Blos­somHill rais­es $100M in bid to re­peat founder­s' can­cer suc­cess at Turn­ing Point

Blos­somHill Ther­a­peu­tics has closed a $100 mil­lion Se­ries B to bring three of its on­col­o­gy small mol­e­cules in­to the clin­ic and col­lect ear­ly ef­fi­ca­cy da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER